Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.05.2014 | case report | Ausgabe 2/2014

memo - Magazine of European Medical Oncology 2/2014

Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology

memo - Magazine of European Medical Oncology > Ausgabe 2/2014
MD Ursula Pluschnig, MD Hans-Jörg Neumann


The patient described here was diagnosed with hormone-receptor-positive breast cancer and underwent numerous treatments in the neoadjuvant, adjuvant and palliative settings. Metastatic disease occurred that was confined to the bone, but kept progressing over several years. Due to the short-lasting nature of the patient’s responses to various endocrine agents, a re-biopsy was performed and a hormone receptor switch to triple negativity was established. With nab-paclitaxel therapy, disease stabilisation has been achieved for 8 months. The patient has tolerated this therapy very well in spite of massive pretreatment.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2014

memo - Magazine of European Medical Oncology 2/2014 Zur Ausgabe